End-of-day quote
Shenzhen S.E.
03:30:00 30/04/2024 am IST
|
5-day change
|
1st Jan Change
|
8.91
CNY
|
+0.34%
|
|
+16.93%
|
-24.94%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,939
|
1,953
|
1,872
|
2,094
|
1,943
|
2,263
|
Enterprise Value (EV)
1 |
1,740
|
1,833
|
1,706
|
1,911
|
1,672
|
1,888
|
P/E ratio
|
78.6
x
|
51.4
x
|
45.1
x
|
49.8
x
|
44.3
x
|
148
x
|
Yield
|
0.29%
|
0.4%
|
0.82%
|
0.91%
|
0.98%
|
-
|
Capitalization / Revenue
|
3.97
x
|
3.53
x
|
3.11
x
|
2.89
x
|
2.27
x
|
3.39
x
|
EV / Revenue
|
3.56
x
|
3.31
x
|
2.83
x
|
2.63
x
|
1.95
x
|
2.83
x
|
EV / EBITDA
|
58
x
|
33.1
x
|
30.7
x
|
29.4
x
|
24.3
x
|
34.1
x
|
EV / FCF
|
-21.2
x
|
-17.7
x
|
45.9
x
|
148
x
|
18.9
x
|
13.4
x
|
FCF Yield
|
-4.72%
|
-5.65%
|
2.18%
|
0.67%
|
5.28%
|
7.44%
|
Price to Book
|
3.14
x
|
3
x
|
2.72
x
|
2.92
x
|
2.61
x
|
3.47
x
|
Nbr of stocks (in thousands)
|
1,89,720
|
1,93,210
|
1,91,769
|
1,91,190
|
1,90,682
|
1,90,678
|
Reference price
2 |
10.22
|
10.11
|
9.760
|
10.95
|
10.19
|
11.87
|
Announcement Date
|
23/04/19
|
27/04/20
|
27/04/21
|
21/04/22
|
26/04/23
|
25/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
488.8
|
553.3
|
602.6
|
725.5
|
856.7
|
667
|
EBITDA
1 |
30
|
55.39
|
55.66
|
64.95
|
68.77
|
55.45
|
EBIT
1 |
20.71
|
44.77
|
39.2
|
41.58
|
46.32
|
31.32
|
Operating Margin
|
4.24%
|
8.09%
|
6.51%
|
5.73%
|
5.41%
|
4.69%
|
Earnings before Tax (EBT)
1 |
28.99
|
47.74
|
47.35
|
50.01
|
56.7
|
23.6
|
Net income
1 |
25.26
|
37.33
|
41.09
|
42.48
|
44.14
|
15.39
|
Net margin
|
5.17%
|
6.75%
|
6.82%
|
5.86%
|
5.15%
|
2.31%
|
EPS
2 |
0.1300
|
0.1968
|
0.2163
|
0.2200
|
0.2300
|
0.0800
|
Free Cash Flow
1 |
-82.09
|
-103.5
|
37.14
|
12.88
|
88.29
|
140.4
|
FCF margin
|
-16.79%
|
-18.71%
|
6.16%
|
1.78%
|
10.31%
|
21.05%
|
FCF Conversion (EBITDA)
|
-
|
-
|
66.72%
|
19.83%
|
128.39%
|
253.25%
|
FCF Conversion (Net income)
|
-
|
-
|
90.37%
|
30.32%
|
200.05%
|
912.69%
|
Dividend per Share
2 |
0.0300
|
0.0400
|
0.0800
|
0.1000
|
0.1000
|
-
|
Announcement Date
|
23/04/19
|
27/04/20
|
27/04/21
|
21/04/22
|
26/04/23
|
25/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
199
|
120
|
165
|
183
|
271
|
375
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-82.1
|
-103
|
37.1
|
12.9
|
88.3
|
140
|
ROE (net income / shareholders' equity)
|
4.13%
|
5.88%
|
6.14%
|
6.18%
|
6.27%
|
2.1%
|
ROA (Net income/ Total Assets)
|
1.74%
|
3.51%
|
2.81%
|
3%
|
3.14%
|
2.01%
|
Assets
1 |
1,455
|
1,063
|
1,462
|
1,416
|
1,405
|
764.9
|
Book Value Per Share
2 |
3.260
|
3.380
|
3.580
|
3.750
|
3.910
|
3.420
|
Cash Flow per Share
2 |
1.260
|
0.8300
|
1.070
|
0.9600
|
1.680
|
1.770
|
Capex
1 |
67.7
|
170
|
38.4
|
25.2
|
3.2
|
3.18
|
Capex / Sales
|
13.85%
|
30.81%
|
6.38%
|
3.47%
|
0.37%
|
0.48%
|
Announcement Date
|
23/04/19
|
27/04/20
|
27/04/21
|
21/04/22
|
26/04/23
|
25/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -24.94% | 235M | | +29.68% | 681B | | +20.01% | 556B | | -4.35% | 361B | | +17.65% | 325B | | +3.77% | 285B | | +13.55% | 235B | | +4.54% | 199B | | -12.23% | 189B | | -3.79% | 157B |
Other Pharmaceuticals
|